|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NLRC5 |
Gene summary for NLRC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NLRC5 | Gene ID | 84166 |
| Gene name | NLR family CARD domain containing 5 | |
| Gene Alias | CLR16.1 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0001959 | UniProtAcc | Q86WI3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84166 | NLRC5 | CCI_1 | Human | Cervix | CC | 7.61e-06 | 5.43e-01 | 0.528 |
| 84166 | NLRC5 | CCI_2 | Human | Cervix | CC | 5.06e-18 | 1.22e+00 | 0.5249 |
| 84166 | NLRC5 | CCI_3 | Human | Cervix | CC | 1.61e-14 | 7.68e-01 | 0.516 |
| 84166 | NLRC5 | sample3 | Human | Cervix | CC | 4.31e-06 | 1.64e-01 | 0.1387 |
| 84166 | NLRC5 | T1 | Human | Cervix | CC | 8.93e-05 | 3.19e-01 | 0.0918 |
| 84166 | NLRC5 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.49e-08 | 3.20e-01 | -0.1954 |
| 84166 | NLRC5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.96e-11 | 6.70e-01 | -0.059 |
| 84166 | NLRC5 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.31e-03 | 8.85e-01 | 0.3487 |
| 84166 | NLRC5 | A002-C-010 | Human | Colorectum | FAP | 8.52e-03 | -1.41e-01 | 0.242 |
| 84166 | NLRC5 | A015-C-203 | Human | Colorectum | FAP | 5.18e-10 | -2.09e-01 | -0.1294 |
| 84166 | NLRC5 | A002-C-203 | Human | Colorectum | FAP | 7.55e-04 | -2.29e-01 | 0.2786 |
| 84166 | NLRC5 | A001-C-108 | Human | Colorectum | FAP | 3.34e-08 | -2.31e-01 | -0.0272 |
| 84166 | NLRC5 | A001-C-104 | Human | Colorectum | FAP | 1.27e-03 | -2.29e-01 | 0.0184 |
| 84166 | NLRC5 | A015-C-106 | Human | Colorectum | FAP | 1.09e-02 | -1.31e-02 | -0.0511 |
| 84166 | NLRC5 | A015-C-104 | Human | Colorectum | FAP | 3.11e-09 | -1.91e-01 | -0.1899 |
| 84166 | NLRC5 | A001-C-014 | Human | Colorectum | FAP | 1.34e-07 | -2.22e-01 | 0.0135 |
| 84166 | NLRC5 | A002-C-016 | Human | Colorectum | FAP | 2.29e-06 | -1.70e-01 | 0.0521 |
| 84166 | NLRC5 | A001-C-203 | Human | Colorectum | FAP | 5.53e-03 | -1.76e-01 | -0.0481 |
| 84166 | NLRC5 | A002-C-116 | Human | Colorectum | FAP | 2.30e-08 | -1.12e-01 | -0.0452 |
| 84166 | NLRC5 | A018-E-020 | Human | Colorectum | FAP | 2.51e-02 | -2.43e-01 | -0.2034 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
| GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
| GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
| GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:00028322 | Cervix | CC | negative regulation of response to biotic stimulus | 27/2311 | 108/18723 | 2.27e-04 | 2.55e-03 | 27 |
| GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
| GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
| GO:00321022 | Cervix | CC | negative regulation of response to external stimulus | 75/2311 | 420/18723 | 5.96e-04 | 5.61e-03 | 75 |
| GO:00450882 | Cervix | CC | regulation of innate immune response | 44/2311 | 218/18723 | 6.40e-04 | 5.97e-03 | 44 |
| GO:00028331 | Cervix | CC | positive regulation of response to biotic stimulus | 35/2311 | 168/18723 | 1.23e-03 | 9.87e-03 | 35 |
| GO:00343415 | Cervix | CC | response to interferon-gamma | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
| GO:00458243 | Cervix | CC | negative regulation of innate immune response | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
| GO:0031348 | Cervix | CC | negative regulation of defense response | 48/2311 | 258/18723 | 2.30e-03 | 1.65e-02 | 48 |
| GO:00603333 | Cervix | CC | interferon-gamma-mediated signaling pathway | 9/2311 | 27/18723 | 3.82e-03 | 2.41e-02 | 9 |
| GO:00713463 | Cervix | CC | cellular response to interferon-gamma | 25/2311 | 118/18723 | 4.54e-03 | 2.75e-02 | 25 |
| GO:00019612 | Cervix | CC | positive regulation of cytokine-mediated signaling pathway | 13/2311 | 50/18723 | 6.42e-03 | 3.58e-02 | 13 |
| GO:00607602 | Cervix | CC | positive regulation of response to cytokine stimulus | 14/2311 | 57/18723 | 8.17e-03 | 4.25e-02 | 14 |
| GO:0045089 | Cervix | CC | positive regulation of innate immune response | 26/2311 | 131/18723 | 9.33e-03 | 4.66e-02 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NLRC5 | SNV | Missense_Mutation | c.4628T>C | p.Met1543Thr | p.M1543T | Q86WI3 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NLRC5 | SNV | Missense_Mutation | c.4839N>C | p.Leu1613Phe | p.L1613F | Q86WI3 | protein_coding | tolerated(0.09) | probably_damaging(0.992) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NLRC5 | SNV | Missense_Mutation | novel | c.2477G>T | p.Arg826Ile | p.R826I | Q86WI3 | protein_coding | deleterious(0.05) | benign(0.298) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NLRC5 | SNV | Missense_Mutation | c.2015N>A | p.Cys672Tyr | p.C672Y | Q86WI3 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| NLRC5 | SNV | Missense_Mutation | c.5086N>T | p.Pro1696Ser | p.P1696S | Q86WI3 | protein_coding | tolerated(0.96) | benign(0.007) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| NLRC5 | SNV | Missense_Mutation | c.3506A>C | p.Gln1169Pro | p.Q1169P | Q86WI3 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NLRC5 | SNV | Missense_Mutation | rs755193749 | c.3028N>A | p.Asp1010Asn | p.D1010N | Q86WI3 | protein_coding | deleterious(0.03) | possibly_damaging(0.683) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| NLRC5 | SNV | Missense_Mutation | c.185A>G | p.His62Arg | p.H62R | Q86WI3 | protein_coding | tolerated(0.34) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| NLRC5 | SNV | Missense_Mutation | c.5270N>A | p.Ala1757Asp | p.A1757D | Q86WI3 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| NLRC5 | SNV | Missense_Mutation | c.2403G>C | p.Arg801Ser | p.R801S | Q86WI3 | protein_coding | tolerated(0.07) | benign(0.011) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |